People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...